Plexiform neurofibromas (PN) arising from the rare disease neurofibromatosis type 1 (NF1) are associated with significant patient morbidity. Surgical resection has been the only available treatment for patients with NF1-associated PN, but surgery is often ineffective or not an option for many of these these patients. The recent development of MEK inhibitors has revolutionized the treatment landscape of NF1-associated PNs, and the latest clinical data concerning novel and emerging MEK inhibitors are paramount for characterizing their use in NF1-associated PN. Join this Clinical Mic Drop as an expert in NF1 reviews pivotal clinical trial data from the latest publications and medical conference presentations concerning therapies for NF1-associated PN.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/clinical-mic-drop-latest-innovations-mek-therapies-neurofibromatosis-type-1
- Start Date: 2024-09-11 05:00:00
- End Date: 2024-09-11 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.25 hours
AMA PRA Category 1 Credit™️: 0.25 hours
Nursing: 0.25 hours
Pharmacy: 0.25 hours - Commercial Support: Source: Springworks Therapeutics - Amount: 24875.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all